Precise Health SA, a dynamic start-up from the Energypolis Campus in Sion and supported by The Ark Foundation, has received the Best Innovation Award at the recent Targeting Phage Therapy Congress in Berlin. This distinction underlines the company’s leadership in developing digital solutions for combating multidrug-resistant bacterial infections, a critical challenge in global healthcare.
In parallel, Precise Health secured a grant of CHF 40,000 from Sion’s innovation stimulus program. These funds will accelerate further development and market positioning of their cutting-edge therapeutic platform and support technical team expansion.
Transforming Phage Therapy with Technology
Precise Health’s platform leverages artificial intelligence and genomics to rapidly identify and match the optimal bacteriophage—viruses that specifically target and destroy bacteria—for each patient’s resistant infection. Traditionally, the process of finding a suitable phage can take up to eight weeks, but this platform reduces it to a matter of hours, dramatically improving patient access to personalized, effective treatments. The platform matches bacterial genome sequences to therapeutic phages from a connected global biobank, supporting clinicians with fast, evidence-based decisions.
This breakthrough is a major step in the fight against antimicrobial resistance, and positions Precise Health as a leader in the evolution of precision anti-infective therapies.
Local Synergy, Global Impact
The combination of regional support and international recognition reflects a strong innovation ecosystem in Valais, capable of advancing transformative projects from concept to clinical reality. Precise Health’s advancements showcase the potential of Swiss biotechnology to deliver solutions with both local and global healthcare impact.
